Psyclo Peptide,Inc.

Shenpeptide Technology is committed to providing biochemical reagents related to peptides and amino acid derivatives for domestic pharmaceutical research and development institutions and research institutions; And customized synthesis technology services Our product line includes various high-end imported brands, as well as domestically owned brands with moderate prices We guarantee the activity and quality of peptide experiments and provide 24-hour technical support Proteins and peptides have a significant and rapidly expanding role as medicines, due to their high affinity, specificity, low toxicity, and ability to alter protein–protein interactions. There are currently over 220 widely launched therapeutic proteins and peptides, compared to 64 antibody-derived drugs. The recombinant and synthetic engineering strategies have advanced from those used to generate the first approved molecules such as insulin over 30 years ago.To date, around 100 therapeutic peptides (mostly innovative synthetic ones) are on the market in the USA, Europe and Japan, including those for diagnostics applications.The therapeutic peptide development is growing. In 2011 alone, there were between 500 and 600 peptides in pre-clinical phases. The year 2012 has proven to be another milestone for the peptide pharmaceutical sector, with 5 and 6 peptides meeting market approval respectively in Europe and in the USA. This was the highest number of approvals ever achieved for new biological entities (NBEs) in one year which renders some optimism to the sector. This optimism is confirmed by the statistics, as the regulatory approval rate for peptides is around 20%, versus 10% for small molecules. In addition, the number of peptides per year entering clinical trials has steadily increased from 1 in 1970 to currently around 20. As of April 2012, the clinical pipeline for peptide drugs was composed of 128 peptide candidates. These included 40 in phase I, 74 in phase II and 14 in phase III. In Phase I, the most represented indications are pain (more than 30%), cancer and cardiovascular diseases. In Phase II and III, in which cancer is the leading target (accounting for more than 15% and 40%, respectively), one finds, next to pain and infectious diseases, also indications not much represented in the current market, such as dermatology, allergies, and CNS disorders.